%D8%AF%D9%8A%D9%86%D9%88%D8%B3%D9%88%D9%85%D8%A7%D8%A8DenosumabDenosumabDenosumabDenosumab%D7%93%D7%A0%D7%95%D7%A1%D7%95%D7%9E%D7%90%D7%91Denosumab%E3%83%87%E3%83%8E%E3%82%B9%E3%83%9E%E3%83%96DenosumabsDenosumab%D0%94%D0%B5%D0%BD%D0%BE%D1%81%D1%83%D0%BC%D0%B0%D0%B1DenosumabDenosumab%D0%94%D0%B5%D0%BD%D0%BE%D1%81%D1%83%D0%BC%D0%B0%D0%B1DenosumabQ408283
about
sameAs
Study Investigating the Effect of Drugs Used to Treat Osteoporosis on the Progression of Calcific Aortic Stenosis.The Treatment of Osteoporosis Using a Combination of Teriparatide (Forteo) and DenosumabSurvival imProvement in Lung cancEr iNduced by DenOsUmab theRapyReduced Dose-density of Denosumab for Unresectable GCTBDenosumab + Pembrolizumab in Patients With Stage IV MelanomaDenosumab in Subjects With Giant Cell Rich Tumors of BoneEvaluation of Denosumab in Combination With Immune Checkpoint Inhibitors in Patients With Unresectable or Metastatic MelanomaStudy of Denosumab as Adjuvant Treatment for Women With High Risk Early Breast Cancer Receiving Neoadjuvant or Adjuvant Therapy (D-CARE)Denosumab in Current Users of Bisphosphonates for Glucocorticoid-induced OsteoporosisMultiple Dose Study to Evaluate the Safety of Multiple Doses of Denosumab 120 mg in Adults With Severe Chronic Kidney Disease (CKD) and CKD on DialysisA Study in Korean Postmenopausal Women With Osteoporosis to Evaluate the Efficacy and Safety of DenosumabSurvey of XGEVA® Presrcibers in Europe to Evaluate Their Knowledge of the Summary of Product Characteristics Pertaining to Osteonecrosis of the JawAMG 162 (Denosumab) Phase 3 Study (DESIRABLE Study) in Patients With Rheumatoid Arthritis on Disease-modifying Antirheumatic Drugs (DMARDs) TreatmentOsteonecrosis of the Jaw (ONJ) and Infection Among Nordic Cancer Patients Treated With XGEVA™ or Zoledronic AcidComparing of the Pharmacokinetic, Safety and Pharmacodynamic of QL1206 and Xgeva® in Healthy AdultsBiomarker Study of the Antitumoral Activity of Denosumab in the Pre- Operative Setting of Early Breast CancerOpen-label Extension Denosumab Study in Children and Young Adults With Osteogenesis ImperfectaStudy of AMG 162 in Subjects With Advanced Cancer Currently Being Treated With Intravenous (IV) BisphosphonatesA Study to Evaluate Denosumab in the Treatment of Postmenopausal OsteoporosisAMG 162 in the Treatment of Bone Loss in Subjects Undergoing Androgen-Deprivation Therapy for Non-metastatic Prostate CancerAMG 162 in the Treatment of Bone Loss in Subjects Undergoing Aromatase Inhibitor Therapy for Non-metastatic Breast CancerEffect of Denosumab in Erosion Healing in RADenosumab in Treating Patients With ER and/or PR Positive, HER2 Negative Metastatic Breast Cancer With Bone Metastases and Detectable Circulating Tumor CellsEfficacy and Safety of Denosumab Compared With Risedronate in Individuals Taking GlucocorticoidsEfficacy and Safety of Romosozumab Treatment in Postmenopausal Women With OsteoporosisComparative Effect of Zoledronic Acid Versus Denosumab on Serum Sclerostin of Postmenopausal Women With Low Bone MassDenosumab in Primary HyperparathyroidismA Study in Indian Postmenopausal Women With Osteoporosis to Evaluate the Efficacy and Safety of DenosumabOpen-Label Access Protocol of Denosumab for Subjects With Advanced CancerEffect of Denosumab on Inflammatory Osteolytic Lesion Activity in Total Hip ArthroplastyEffects of Denosumab on the Pharmacokinetics of EtanerceptRANKL Inhibition and Breast Tissue BiomarkersComparative Antiresorptive Efficacy Discontinuation of DenosumabStudy Comparing Denosumab With Standard Treatment in Urothelial Cancer Patients With Bone MetastasesA Study to Evaluate the Denosumab in Healthy AdultsBisphosphonates for Prevention of Post-Denosumab Bone LossDenosumab: A Potential Treatment Option for Aneurysmal Bone CystsEfficacy of Denosumab on Normal BMD in Women Receiving Adjuvant Aromatase Inhibitors for Early Breast CancerDenosumab in Treating Patients With Bone Loss Due to Donor Stem Cell TransplantPhase 1 Study to Compare CMAB807 Injection to Prolia® in Healthy Volunteers
P4844
Q1344835-C1D669C6-C69A-4ED0-ACE2-7088DC58CC1DQ1474877-A8C40F0A-3112-43A7-B1CA-55C38AAF5441Q165328-53D598B6-7F2F-4468-A7E7-71CC0F2FF408Q193078-A3F32E10-E35A-4008-83DC-242E299E5FD5Q223591-5FCA0FB2-2A49-4C95-8D20-CEF390DF7539Q298230-7519B63D-E3C9-46ED-B7AB-8ADC799E35D4Q3658562-4780F052-EAED-4480-B02D-86B762A4CF39Q4116663-612AF436-6CD7-4C1D-9BF2-8A30F7E77027Q4761773-B17C82BD-9904-4AB9-B767-6EE9ACD3BC19Q4941552-2AE00439-2C92-4599-A23D-C096A6D833CFQ55781316-B140CC85-7041-4978-9ED2-C11D151F4ACEQ55785783-5B0B4135-B73E-4363-857B-1FD8F95BA466Q55950294-58C39FA2-DC05-4A53-89E5-EDFA873893FEQ68833-AC507461-4059-467E-BFA7-98B92F5733E0Q860395-B27030D8-9F78-4A72-BBBE-986520D32FBB
P2176
Q61894276-0676399A-48D0-4084-84A1-1349966300B6Q61894360-EDF29084-DA47-4456-835C-E1E3026CFB2EQ61894457-6C22B604-138E-4C65-8B14-64EDE4FD1948Q61902711-8086B60B-5D0F-454F-BC7D-E28B0BC7E0E2Q61902725-FBCE0011-AC5E-4D0D-8644-874F28C5D3C2Q61907332-DF95BE4C-153E-44A7-BDB4-6B59561490A7Q61909169-30F8E2C5-3B1A-4F0C-9A9F-F8076CFACCB2Q61938058-D8C0BC6A-5461-4A1F-A151-097CF71A8826Q61956544-44C76628-3FA1-46EA-9521-5B8C01587185Q61956643-5A887C80-62AC-43E8-83AE-96A58122613EQ61965919-E6E4DA57-BBEB-4A20-9B60-AA6182BF37DBQ61969433-129A7CB4-DA15-44F7-979E-1BCB90C7958CQ61975109-029470BC-3A1D-477F-B91D-3643351EC099Q61975612-AFF63F19-4B93-4E71-8127-4453C80AF2B1Q62025297-B6882322-3260-48E3-A042-92CCBD7B21F1Q62054095-4C3D5E67-E763-466F-B96D-4E56F11C0027Q62063147-FF1E53D3-4048-4C73-BA4C-3AF9602ACDB2Q62105850-1FEAC635-BAF7-4F48-9390-C6FAC14618D8Q62109985-7BAAB669-3925-45A7-9287-25C070F0FF4EQ62110020-6E88185E-6A79-4967-A0AF-8B452FE28A68Q62110022-C9F28F0A-1146-4275-BC41-028D4B696BFDQ63010595-FDADDF38-9788-48A7-8E9A-B95CB6F1FFACQ63229134-11AF732E-17D3-4D17-A390-A978B9F9F0EDQ63315746-A4E0D22B-DBD9-4B6F-BD2C-90BD2C788B4BQ63315750-44846987-BF59-47B3-9459-51E1025B1A5BQ63316305-D90D9504-A722-4735-90C4-53A8E106985FQ63317563-9E1B0C9A-326C-4FBB-B20A-79E9BC3410ACQ63319553-6FEE23AD-F1C0-4812-BA5C-9431E9D7D675Q63322401-A073487D-A70A-4F92-9C27-9F10DF67C297Q63335956-E592CD9D-974D-4394-99C0-6BCAC839AC32Q63339399-C384FB35-5461-4D73-8507-26152021687EQ63393082-FBB8261F-F508-45C4-9B92-D3948A2D3982Q63393844-306B0059-BE73-4FB2-A928-31B9685F9F6EQ63397553-1B71FC22-F95C-4B46-84EE-8EAC60659FC4Q63401114-CC3F7EDA-CE8E-4DA1-96A7-EEDA64858BA3Q63403604-AC450CA5-B04E-4606-8321-1D5C4AA30964Q63405057-18903071-728C-421D-BFB8-FE2491AFDA50Q63534450-4C4EFC24-4DB4-4558-B2F9-C9A04FAE1215Q63573124-AC575766-2C9E-47DB-8493-ADEC81C09535Q63573334-67A70073-CA61-4938-A34C-C3A651163202
P4844
description
Protein
@de
chemesch Verbindung
@lb
chemical compound
@en-ca
chemical compound
@en-gb
chemická sloučenina
@cs
chemická zlúčenina
@sk
chemiese verbinding
@af
chemische Verbindung
@de-ch
component quimic
@oc
compositum chemicum
@la
name
Denosumab
@de
Denosumab
@es
Denosumab
@it
Denosumab
@nl
Denosumab
@sh
Denosumab
@sr
Denosumab
@vi
Denosumab抗體
@zh
denosumab
@cs
denosumab
@en
type
label
Denosumab
@de
Denosumab
@es
Denosumab
@it
Denosumab
@nl
Denosumab
@sh
Denosumab
@sr
Denosumab
@vi
Denosumab抗體
@zh
denosumab
@cs
denosumab
@en
altLabel
AMG-162
@en
Prolia
@de
Prolia
@es
Prolia, Ranmark Xgeva
@en
地诺单抗
@zh
prefLabel
Denosumab
@de
Denosumab
@es
Denosumab
@it
Denosumab
@nl
Denosumab
@sh
Denosumab
@sr
Denosumab
@vi
Denosumab抗體
@zh
denosumab
@cs
denosumab
@en
P2175
P31
P486
P592
P6366
P646
P665
P176
P2115
N0000181718
P2175
P2275
Denosumab
@en
P231
615258-40-7
P267
P3345
P486
D000069448
P592
CHEMBL1237023
P6366
2776286101
P646
/m/027v8r1
P652
4EQZ6YO2HI